Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Early Glaucoma Screening Using the Ibopamine Provocative Test

Domínguez-Dueñas, Francisca MD, MSc; Plaza-Espinosa, Leticia MD, MSc; Mundo-Fernández, Eva E. MD; Jiménez-Reynoso, Celeste A. MD; Barojas-Weber, Everardo MD; Barrientos-Gutiérrez, Tonatiuh MD, PhD

doi: 10.1097/IJG.0000000000000343
Online Articles: Original Studies

Purpose: To evaluate the diagnostic ability of the ibopamine provocative test for early glaucoma detection.

Method: A sample of 44 patients with suspicious optic discs was recruited and compared with 37 controls with normal optic discs and no ocular pathology. The ibopamine test was performed in all patients who were then followed up with diagnostic tests for glaucoma, visual fields, and spectral-domain optical coherence tomography.

Results: Early glaucoma was diagnosed in 26 patients. The sensitivity of the ibopamine test to discriminate patients who had early glaucoma was 78.7%, with a specificity of 71.6%. In multivariable analyses adjusted for demographic and clinical variables, participants with a positive ibopamine test at baseline had an 8-fold higher risk of glaucoma compared with those who had a negative test; glaucoma risk was highest among ibopamine-positive subjects with initial clinical diagnostic impression of glaucoma.

Conclusions: The ibopamine test showed an adequate diagnostic performance to detect individuals at increased risk of glaucoma in a very early stage of the disease. While further studies are required, the provocative ibopamine test for the diagnosis of early glaucoma is promissory.

*Department of Ophthalmology, National Rehabilitation Institute of Mexico, Medicine School of The National Autonomous University of Mexico

Ophthalmologic Clinic Anzures, Mexican Glaucoma Society, México City

The National Institute of Public Health of Mexico, México

Disclosure: The authors declare no conflict of interest.

Reprints: Francisca Domínguez-Dueñas, MD, MSc, Calzada México Xochimilco 289, Arenal de Guadalupe, Tlalpan, CP 14389, Ciudad de México, Distrito Federal, México (e-mail: fran_dd@yahoo.com).

Received September 4, 2014

Accepted September 28, 2015

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.